Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anaptysbio (ANAB) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Anaptysbio (ANAB) over the last 10 years, with Q3 2025 value amounting to 19.87%.

  • Anaptysbio's EBITDA Margin rose 1254000.0% to 19.87% in Q3 2025 from the same period last year, while for Sep 2025 it was 56.39%, marking a year-over-year increase of 2279300.0%. This contributed to the annual value of 157.9% for FY2024, which is 7698300.0% up from last year.
  • Anaptysbio's EBITDA Margin amounted to 19.87% in Q3 2025, which was up 1254000.0% from 174.27% recorded in Q2 2025.
  • In the past 5 years, Anaptysbio's EBITDA Margin ranged from a high of 19.87% in Q3 2025 and a low of 3945.05% during Q1 2022
  • Moreover, its 5-year median value for EBITDA Margin was 451.5% (2023), whereas its average is 1093.1%.
  • Examining YoY changes over the last 5 years, Anaptysbio's EBITDA Margin showed a top increase of 27273200bps in 2022 and a maximum decrease of -37623500bps in 2022.
  • Over the past 5 years, Anaptysbio's EBITDA Margin (Quarter) stood at 3240.36% in 2021, then surged by 84bps to 513.04% in 2022, then increased by 12bps to 451.5% in 2023, then skyrocketed by 80bps to 88.95% in 2024, then surged by 122bps to 19.87% in 2025.
  • Its last three reported values are 19.87% in Q3 2025, 174.27% for Q2 2025, and 142.14% during Q1 2025.